Inovio Swoons as Covid Vaccine Trial Slowed on FDA Queries (1)

Inovio Pharmaceuticals Inc. put a partial hold on a phase 2-3 study of its Covid-19 vaccine after U.S. regulators raised questions about a delivery device used in the inoculation. The shares plunged.

The vaccine maker is working to answer questions from the U.S. Food and Drug Administration about the Cellectra 2000 device used in the trial, Plymouth Meeting, Pennsylvania-based Inovio said Monday in a statement. The hold is not due to any adverse events from the vaccine, Inovio said.

The company plans to respond in October, after which the FDA will have 30 days to notify Inovio with a decision ...